Coronado Biosciences to Present at the ROTH 25th Annual Growth Stock
BURLINGTON, Mass., March 11, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences,
Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of
novel immunotherapy biologic agents for the treatment of autoimmune diseases
and cancer, announced today that Dr. Harlan F. Weisman, Coronado's Chairman
and CEO, will present at the at the ROTH 25th Annual Growth Stock Conference
on Monday, March 18, 2013, at 12:30 PM PDT. The conference will be held at the
Ritz-Carlton, Laguna Niguel in Dana Point, CA on March 17-20, 2013. A webcast
of the presentation will be available at www.coronadobiosciences.com on the
Events & Webcasts page.
About Coronado Biosciences
Coronado Biosciences is engaged in the development of novel immunotherapy
biologic agents. The company's two principal pharmaceutical product candidates
in clinical development are: TSO (Trichuris suis ova or CNDO-201), a biologic
for the treatment of autoimmune diseases, such as Crohn's disease, ulcerative
colitis and multiple sclerosis; and CNDO-109, a biologic that activates
natural killer (NK) cells, for the treatment of acute myeloid leukemia (AML),
multiple myeloma and solid tumors. For more information, please visit
The Coronado Biosciences, Inc. logo is available at
This press release may contain "forward-looking statements" within the meaning
of Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. Such statements include, but are not limited to, any
statements relating to the company's product development programs and any
other statements that are not historical facts. Forward-looking statements are
based on management's current expectations and are subject to risks and
uncertainties that could negatively affect our business, operating results,
financial condition and stock price. Factors that could cause actual results
to differ materially from those currently anticipated include risks relating
to the results of research and development activities, uncertainties relating
to preclinical and clinical testing, our ability to attract, integrate and
retain key personnel, financing and strategic agreements and relationships,
the early stage of products under development, our need for substantial
additional funds, government regulation, patent and intellectual property
matters; our dependence on third party suppliers and competition, as well as
other risks described in our SEC filings.We expressly disclaim any obligation
or undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change in our
expectations or any changes in events, conditions or circumstances on which
any such statement is based, except as required by law.
CONTACT: Lucy Lu, MD, Executive Vice President
& Chief Financial Officer
Coronado Biosciences, Inc.
Marcy Nanus, Vice President
The Trout Group, LLC.
Dian Griesel Inc.
Coronado Biosciences logo
Press spacebar to pause and continue. Press esc to stop.